Pembrolizumab + CCRT ups survival in high-risk LACC
8 hours ago
byElaine Soliven
Treatment with the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT), followed by pembrolizumab maintenance, led to a sustained, long-term survival benefit in patients with high-risk, locally advanced cervical cancer (LACC) compared with CCRT alone, according to the final analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at ASCO 2025.